A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism

Myopia Clinical Trial

Official title:

A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04111757
• Other study ID #: 884
• Status: Completed
• Phase: N/A
• Start date: July 25, 2019
• Est. completion date: August 6, 2021

Study information

• Verified date: May 2022
• Source: Bausch & Lomb Incorporated
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to collect safety and effectiveness data for the Technolas Teneo 317 Model 2 excimer laser for LASIK correction in participants with myopia and myopic astigmatism.

Description:

Technolas TENEO 317 Model 2 excimer laser is a scanning excimer laser that operates at 193 nm ultraviolet wavelength to photoablate corneal tissue in order to achieve a refractive change. It is planned to enroll and treat up to 334 participant eyes, with an expectation that 300 study eyes will complete post-surgical follow-up for 6 months or until the point of achieved refractive stability. When a cohort of at least 300 eyes has achieved refractive stability at 6 months post-surgery, all other treated eyes that have not reached the 6-month examination may be discontinued at the Sponsor's request. Or, if 300 eyes achieve refractive stability at 9 months post-surgery, all other treated eyes that have not reached the 9-month examination may be discontinued

Recruitment information / eligibility

• Status: Completed
• Enrollment: 168
• Est. completion date: August 6, 2021
• Est. primary completion date: August 6, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• Are 22 years of age or older.

• Have read, understood, and signed an informed consent form (ICF).

• Have demonstrated stable refraction (for example, a change of =0.5 D in sphere and cylinder) for a minimum of 12 months prior to surgery, verified by consecutive refractions and/or medical records or prescription history.

• Have myopic refractive error with or without astigmatism; sphere between -1.0 D and -10.00 D, cylinder between 0.0 D and -3.0 D; with a manifest refraction spherical equivalent (MRSE) between -1.0 D and -11.50 D.

• Have uncorrected distance visual acuity (UDVA) of 20/40 or worse.

• Have manifest distance best spectacle corrected visual acuity (BSCVA) of 20/25 (logarithm of the minimum angle of resolution [logMAR] 0.1) or better in an operative eye.

• Have equal to or less than 0.50 D spherical equivalent (SE) difference between cycloplegic and manifest refractions at Visit 1 (pre-operative).

• Have normal corneal topography as determined by the Investigator.

• Have discontinued use of contact lenses for at least 2 weeks (for hard or toric lenses) or 3 days (for soft contact lenses) prior to the pre-operative examination, and through the day of surgery.

• All contact lens wearers must demonstrate a stable refraction (within ±0.5 D), as determined by MRSE, on 2 consecutive examinations at least 1 week apart, in an eye to be treated and the axis of cylinder should not differ by more than 15 degrees from the baseline cycloplegic refraction.

• Have the ability to lie flat without difficulty.

• Are willing and able to comply with the schedule for all post-surgery follow-up visits.

Exclusion Criteria:

• Participants for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in treatment depth less than 250 microns from corneal endothelium.

• Eyes for which the baseline manifest subjective refraction exhibits a difference greater than 0.50 D in sphere power, or a difference greater than 0.50 D in cylinder power, or a difference in cylinder axis of more than 15 degrees compared to the baseline cycloplegic subjective refraction. For manifest cylinder of less than 0.50 D, the difference in cylinder axis will not be taken into consideration.

• Participants for whom the pre-operative assessment of the cornea indicates that one or both eyes are not suitable candidates for treatment based upon the Investigator's medical judgment.

• Have evidence of retinal vascular disease.

• Have a history of or have active corneal disease or infection (for example, recurrent corneal erosion syndrome, herpes simplex, or herpes zoster keratitis) in either eye.

• Have a known sensitivity to any study medication.

• Have central corneal scars affecting visual acuity or unstable keratometry with irregular mires in an eye considered for eligibility.

• Have keratoconus, subclinical or forme fruste keratoconus, corneal dystrophy, or other corneal irregularity (for example, irregular astigmatism).

• Have visually significant or progressive cataract in an eye considered for eligibility.

• Had previous intraocular or corneal surgery in an eye considered for eligibility that might confound the outcome of the study or increase the risk to the participant.

• Use chronic medications by any administration route that may increase risk to the participant or may confound the outcome of the study, including those known to affect wound healing (for example, corticosteroids, antimetabolites).

• Are known to have acute or chronic disease or illness (for example, dry eye, cataract, glaucoma, immuno-compromised, rheumatoid arthritis, clinically significant atopic disease, acne rosacea) that would increase operative risk or may confound the results of the study.

• Are taking medications contraindicated for LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone).

• Are known to be pregnant, lactating, or who plan to become pregnant during the course of the study.

• Have known sensitivity to medications used for standard LASIK.

• Have the presence of systemic disease likely to affect wound healing, for example, autoimmune disease, systemic connective tissue disease, diabetes, or severe atopic disease.

• Are participating in any other ophthalmic clinical trial within 30 days of screening or during this clinical trial.

• Have an ocular muscle disorder including a strabismus or nystagmus, or other disorder affecting fixation.

• Have a history of or evidence of glaucoma or are a glaucoma suspect.

• Have eyes with mesopic pupil size >7.0 millimeters (mm).

• Have a Schirmer's pre-operative test without anesthesia <4 mm/5 minutes.

Related Conditions & MeSH terms

• Astigmatism
• Myopia
• Myopic Astigmatism

Intervention

Device:
• Technolas® TENEO 317 Model 2
LASIK eye surgery

Locations

Country	Name	City	State
United States	Bausch Site 102	Amherst	New York
United States	Bausch Site 110	Blaine	Minnesota
United States	Bausch Site 107	Bloomington	Minnesota
United States	Bausch Site 105	Cedar Park	Texas
United States	Bausch Site 104	Greensboro	North Carolina
United States	Bausch Site 103	Mount Pleasant	South Carolina
United States	Bausch Site 101	Newport Beach	California
United States	Bausch Site 108	Omaha	Nebraska
United States	Bausch Site 106	Portsmouth	New Hampshire
United States	Bausch Site 109	Sioux Falls	South Dakota

Sponsors (1)

Lead Sponsor	Collaborator
Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Eyes That Achieve MRSE Predictability Within ±0.50 Diopter (D) and ±1.00 D	Predictability is defined as the difference between the attempted and achieved manifest refraction spherical equivalent (MRSE) at the time of refractive stability.	Assessed at Month 3 to Month 9
Primary	Percentage of Eyes Targeted for Emmetropia That Achieve Uncorrected Distance Visual Acuity (UDVA) of 20/40 or Better	Percentage of eyes targeted for emmetropia that achieve UDVA of 20/40 or better at the point at which refractive stability is reached.	Assessed at Month 3 to Month 9